Opened in May 2017, BGI Australia laboratory is BGI’s first genomic sequencing laboratory located in the southern hemisphere. The
460 m2 purpose-built laboratory, with segregation of multiple processing areas and strict quality management system to ensure accurate and efficient sample preparation, hosts BGI’s proprietary DNBSEQTM genome-sequencing platforms such as ultra-high-throughput sequencer DNBSEQ-T7, high-throughput sequencer DNBSEQ-G400 and small-to-medium-throughput sequencer DNBSEQ-G50. The DNBSEQ-G400 and DNBSEQ-G50 sequencer have received TGA approval in Australia and international certifications including CE Marking, CB Certification and CFDA (China Food and Drug Administration). The state-of-the-art facility currently has the capacity to sequence approximately 5,000 Whole Exome sequencing samples or 2,000 Whole Genome sequencing samples per year. The lab has been empowering Australian scientists in their cutting-edge research with quality sequencing services and bioinformatics analysis for different species (human, plant, animal, microorganism), ranging from DNA level (Whole genome, Metagenome and Exome sequencing), RNA level (transcriptome, quantification, RNA sequencing). This October the lab received NATA accreditation for clinical Whole Exome Sequencing and is now also offering clinical services to benefit the broad community.
Building on lessons from the accreditation process, BGI Australia will look to expand its testing scope and demonstrate its capabilities in clinical solutions, as well as seek partnerships in technology transfer to make testing more accessible to the community.